What is Lozaris?
Lozaris is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure may reduce the risk of strokes and heart attacks.
Lozaris is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, Lozaris relaxes the blood vessels. A lower blood pressure will increase the supply of the blood and oxygen to the heart.
Lozaris is also used to decrease the risk of stroke in patients with high blood pressure and enlargement of the heart. It is also used to treat kidney problems in patients with type 2 diabetes and a history of hypertension.
Lozaris is available only with your doctor's prescription.
Lozaris indications
Lozaris is used to treat high blood pressure (hypertension). High blood pressure adds to the work load of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Lozaris works by blocking the action of a substance in the body that causes blood vessels to tighten. As a result, Lozaris relaxes blood vessels. This lowers blood pressure.
Lozaris is also used to decrease the risk of stroke in patients with high blood pressure and a condition called left ventricular hypertrophy (LVH). LVH is an enlargement of the left pumping chamber of the heart and can cause problems with the way the heart pumps blood.
Lozaris is also used to treat a condition called diabetic nephropathy. Diabetic nephropathy is a complication of type 2 diabetes which causes the kidneys to not work properly.
How should I use Lozaris?
Use Lozaris as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Lozaris. Talk to your pharmacist if you have questions about this information.
- Take Lozaris by mouth with or without food.
- If you cannot swallow tablets, ask your doctor or pharmacist about preparing a suspension of Lozaris.
- Take Lozaris on a regular schedule to get the most benefit from it. Taking Lozaris at the same time each day will help you remember to take it.
- Continue to take Lozaris even if you feel well. Do not miss any doses.
- If you miss a dose of Lozaris, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Lozaris.
Uses of Lozaris in details
Use: Labeled Indications
Hypertension: Management of hypertension in adults and children ≥6 years of age
Proteinuric chronic kidney disease, diabetic: Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension
Off Label Uses
Heart failure with reduced ejection fraction
Data from a randomized, double-blind, dose comparison study in patients with New York Heart Association (NYHA) class II to IV heart failure support the use of Lozaris at higher doses to reduce the rate of death or admission for heart failure in patients with heart failure.
Proteinuric chronic kidney disease, nondiabetic
Based on the 2012 Kidney Disease Improving Global Outcomes guidelines, the use of an ACE inhibitor or an ARB is recommended in patients with proteinuric CKD to prevent progression of CKD.
ST-elevation myocardial infarction
Based on the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infraction, an ARB is recommended and effective in patients who have indications for but are intolerant of ACE inhibitors.
Lozaris description
Lozaris POTASSIUM (Lozaris), the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT1) antagonist. Lozaris POTASSIUM (Lozaris) also provides a reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy and renal protection for type 2 diabetic patients with proteinuria.
Lozaris potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt.
Its empirical formula is C22H22ClKN6O.
Lozaris potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of Lozaris.
Lozaris dosage
Hypertension: The usual starting and maintenance dose is 50 mg once daily for most patients. The maximal antihypertensive effect is attained 3-6 weeks after initiation of therapy. Some patients may receive an additional benefit by increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered.
No initial dosage adjustment is necessary for elderly patients or for patients with renal impairment, including patients on dialysis. A lower dose should be considered for patients with a history of hepatic impairment.
Reduction in the Risk of Cardiovascular Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy: The usual starting dose is 50 mg of Lozaris POTASSIUM (Lozaris) once daily. A low dose of hydrochlorothiazide should be added and/or the dose of Lozaris POTASSIUM (Lozaris) should be increased to 100 mg once daily based on blood pressure response.
Renal Protection in Type 2 Diabetic Patients with Proteinuria: The usual starting dose is 50 mg once daily. The dose may be increased to 100 mg once daily based on blood pressure response. Lozaris POTASSIUM (Lozaris) may be administered with other antihypertensive agents (e.g., diuretics, calcium channel blockers, alpha- or beta-blockers, and centrally acting agents) as well as with insulin and other commonly used hypoglycemic agents (e.g., sulfonylureas, glitazones and glucosidase inhibitors).
Administration: Lozaris POTASSIUM (Lozaris) may be administered with or without food.
Lozaris POTASSIUM (Lozaris) may be administered with other antihypertensive agents.
Lozaris interactions
See also:
What other drugs will affect Lozaris?
Concomitant use of Lozaris with fenofibrate is beneficial in the treatment of patients with gout and hypertriglyceridemia.
Lozaris shows no effect on the pharmacokinetics of warfarin and digoxin.
Administration of Lozaris with fluconazole, phenytoin and grapefruit juice inhibits the metabolism of Lozaris to its active metabolite. Although not yet established, the possibility of decreased therapeutic effect of Lozaris may be considered.
Rifampicin was found to induce the metabolism of Lozaris to its active metabolite, E3174 thereby, reducing levels of both Lozaris and E3174 in the circulation.
Lozaris does not affect the pharmacokinetic properties of phenytoin and orlistat.
Administration of Lozaris with spironolactone and other potassium-sparing diuretics may lead to the occurrence of hyperkalemia. Physicians are advised to monitor patient's serum potassium level.
The use of Lozaris with ACE inhibitors and β-blockers potentiates the antihypertensive effects of Lozaris.
There have been reports of lithium intoxication when Lozaris was given to patients treated with lithium.
Lozaris side effects
See also:
What are the possible side effects of Lozaris?
Lozaris POTASSIUM (Lozaris) has been found to be generally well tolerated in controlled clinical trials for hypertension; side effects have usually been mild and transient in nature and have not required discontinuation of therapy. The overall incidence of side effects reported with Lozaris POTASSIUM (Lozaris) was comparable to placebo.
In controlled clinical trials for essential hypertension, dizziness was the only side effect reported as drug related that occurred with an incidence greater than placebo in one percent or more of patients treated with Lozaris POTASSIUM (Lozaris). In addition, dose-related orthostatic effects were seen in less than one percent of patients. Rarely, rash was reported, although the incidence in controlled clinical trials was less than placebo.
In these double-blind controlled clinical trials for essential hypertension, the following adverse experiences reported with Lozaris POTASSIUM (Lozaris) occurred in ≥1 percent of patients, regardless of drug relationship:
Lozaris POTASSIUM (Lozaris) was generally well tolerated in a controlled clinical trial in hypertensive patients with left ventricular hypertrophy. The most common drug-related side effects were dizziness, asthenia/fatigue, and vertigo.
In the LIFE study, among patients without diabetes at baseline, there was a lower incidence of new onset diabetes mellitus with Lozaris POTASSIUM (Lozaris) as compared to atenolol (242 patients versus 320 patients, respectively, p<0.001). Because there was no placebo group included in the study, it is not known if this represents a beneficial effect of Lozaris POTASSIUM (Lozaris) or an adverse effect of atenolol.
Lozaris POTASSIUM (Lozaris) was generally well tolerated in a controlled clinical trial in type 2 diabetic patients with proteinuria. The most common drug-related side effects were asthenia/fatigue, dizziness, hypotension and hyperkalemia.
The following additional adverse reactions have been reported in post-marketing experience: Hypersensitivity: Anaphylactic reactions, angioedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx and/or tongue has been reported rarely in patients treated with Lozaris; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Vasculitis, including Henoch-Schoenlein purpura, has been reported rarely.
Gastrointestinal: Hepatitis (reported rarely), liver function abnormalities, vomiting.
General Disorders and Administration Site Conditions: Malaise.
Hematologic: Anemia, thrombocytopenia (reported rarely).
Musculoskeletal: Myalgia, arthralgia.
Nervous System/Psychiatric: Migraine, dysgeusia.
Reproductive System and Breast Disorders: Erectile dysfunction/impotence.
Respiratory: Cough.
Skin: Urticaria, pruritus, erythroderma, photosensitivity.
Laboratory Test Findings: In controlled clinical trials for essential hypertension, clinically important changes in standard laboratory parameters were rarely associated with administration of Lozaris POTASSIUM (Lozaris). Hyperkalemia (serum potassium >5.5 mEq/L) occurred in 1.5% of patients in the hypertension clinical trials. In a clinical study conducted in type 2 diabetic patients with proteinuria, 9.9% of patients treated with Lozaris POTASSIUM (Lozaris) and 3.4% of patients treated with placebo developed hyperkalemia. Elevations of ALT occurred rarely and usually resolved upon discontinuation of therapy.
Lozaris contraindications
See also:
What is the most important information I should know about Lozaris?
Do not use if you are pregnant. Stop using and tell your doctor right away if you become pregnant. Lozaris can cause injury or death to the unborn baby if you take the medicine during your second or third trimester. Use effective birth control.
You should not use this medication if you are allergic to Lozaris.
Before you use Lozaris, tell your doctor about all your other medical conditions and allergies. Also make sure your doctor knows if you are pregnant or breast-feeding. In some cases, you may not be able to use Lozaris, or you may need a dose adjustment or special precautions.
Certain other drugs may interact with Lozaris or should not be used at the same time. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.
Call your doctor if you have ongoing vomiting or diarrhea, or if you are sweating more than usual. You can easily become dehydrated while taking this medicine, which can lead to severely low blood pressure or a serious electrolyte imbalance.
In rare cases, Lozaris can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.
Active ingredient matches for Lozaris:
Losartan in Philippines.
Losartan K in Philippines.
| Unit description / dosage (Manufacturer) | Price, USD |
| Lozaris 50 mg x 100's | $ 21.11 |
List of Lozaris substitutes (brand and generic names): | |
| Lozarep (Hungary, Serbia) | |
| Lozarsin (South Korea) | |
| Lozart (Philippines) | |
| Lozart 100 100 mg x 100's | |
| Lozart 50 50 mg x 100's | |
| Lozart 50/Lozart 100 (Philippines) | |
| Lozarten (Colombia) | |
| Lozasartan (South Korea) | |
| Lozatan (Greece) | |
| Lozato (South Korea) | |
| Lozet (South Korea) | |
| Lozitan (India) | |
| Lozitan Capsule/ Tablet / 50mg / 10 units (Wockhardt) | $ 0.47 |
| Lozitan Capsule/ Tablet / 25mg / 10 units (Wockhardt) | $ 0.23 |
| Lozitan 25mg TAB / 10 (Wockhardt) | $ 0.23 |
| Lozitan 50mg TAB / 10 (Wockhardt) | $ 0.47 |
| 25 mg x 10's (Wockhardt) | $ 0.23 |
| 50 mg x 10's (Wockhardt) | $ 0.47 |
| LOZITAN tab 25 mg x 10's (Wockhardt) | $ 0.23 |
| LOZITAN tab 50 mg x 10's (Wockhardt) | $ 0.47 |
| Lozitan 25mg Tablet (Wockhardt) | $ 0.02 |
| Lozitan 50mg Tablet (Wockhardt) | $ 0.05 |
| Lozydel (Mexico) | |
| Lpcare (India) | |
| LPCARE tab 25 mg x 10's (Lifecare) | $ 0.36 |
| LPCARE tab 50 mg x 10's (Lifecare) | $ 0.76 |
| Lps | |
| Lps 50mg Tablet (Plus Pharma) | $ 0.05 |
| Lps Plus 50mg/12.5mg Tablet (Plus Pharma) | $ 0.05 |
| LTK | |
| LTK 25 MG TABLET 1 strip / 10 tablets each (Unison Pharmaceuticals Pvt Ltd) | $ 0.11 |
| LTK 50 MG TABLET 1 strip / 10 tablets each (Unison Pharmaceuticals Pvt Ltd) | $ 0.22 |
| Ltk 25mg Tablet (Unison Pharmaceuticals Pvt Ltd) | $ 0.01 |
| Ltk 50mg Tablet (Unison Pharmaceuticals Pvt Ltd) | $ 0.02 |
| LTP (India) | |
| 25 mg x 10's (Sigman) | $ 0.22 |
| 50 mg x 10's (Sigman) | $ 0.31 |
| Ltp 25mg TAB / 10 (Sigman) | $ 0.22 |
| Ltp 50mg TAB / 10 (Sigman) | $ 0.31 |
| LTP tab 25 mg x 10's (Sigman) | $ 0.22 |
| LTP tab 50 mg x 10's (Sigman) | $ 0.31 |
| Ltp 25mg TAB / 10 (Sigman) | $ 0.22 |
| Ltp 50mg TAB / 10 (Sigman) | $ 0.31 |
| Lyosan (Greece) | |
| MAINSTAY | |
| MAINSTAY 25MG TABLET 1 strip / 10 tablets each (Gold Line) | $ 0.29 |
| MAINSTAY 50MG TABLET 1 strip / 10 tablets each (Gold Line) | $ 0.57 |
| Mainstay 50mg Tablet (Gold Line) | $ 0.06 |
| Medzar (Tunisia) | |
See 2104 substitutes for Lozaris | |
References
- DailyMed. "LOSARTAN POTASSIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "losartan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "losartan". http://www.drugbank.ca/drugs/DB00678 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lozaris are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lozaris. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
